港股異動丨控股權易手,東京中央拍賣飆升1.12倍後漲幅大幅收窄
東京中央拍賣(1939.HK)控股權易手,今早復牌後急升,一度飆升1.12倍至3.18港元,但隨後回落,目前漲幅收窄至10%以內,截至目前成交逾3400萬港元。集團宣佈,控股股東安藤湘等,向瑞和數智(3680.HK) 、李傑峯及鄭浩然等出售近3.75億股東京中央拍賣股份,相當全部已發行股本約74.99%,代價爲1.65億港元,相當於每股待售股份0.44港元,較停牌前1.5港元折讓約70.67%。收購方擬在要約結束後,維持東京中央拍賣在聯交所的上市地位,也無意行使任何強制收購任何發行在外股份的權力。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.